IP Verse

Antibodies, Compounds And Derivatives Thereof For Use In The Treatment Of Male Infertility - EP3030249

The patent EP3030249 was granted to Fertilitypro APS on Dec 25, 2019. The application was originally filed on Aug 4, 2014 under application number EP14750142A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3030249

FERTILITYPRO APS
Application Number
EP14750142A
Filing Date
Aug 4, 2014
Status
Granted And Under Opposition
Nov 22, 2019
Publication Date
Dec 25, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PATENTANWALTE ISENBRUCK BOSL HORSCHLER PARTG MBBSep 24, 2020SIMMONS & SIMMONS MUNICHADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS4411993
DESCRIPTIONUS4703004
DESCRIPTIONUS4816567
DESCRIPTIONUS4946778
DESCRIPTIONUS5260203
DESCRIPTIONWO2013067639
DESCRIPTIONWO8801649
INTERNATIONAL-SEARCH-REPORTWO2007020042
INTERNATIONAL-SEARCH-REPORTWO2010022120
OPPOSITIONEP3030249
OPPOSITIONWO02098362
OPPOSITIONWO2008088594
OPPOSITIONWO2012064967
OPPOSITIONWO2014113260
OPPOSITIONWO2014135611

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BECKMAN ET AL., J. IMMUNOL., (1990), vol. 144, page 4212
DESCRIPTION- BLOMBERG JENSEN M ET AL., "Characterization of the testicular, epididymal and endocrine phenotypes in the Leuven Vdr-deficient mouse model: targeting estrogen signalling", MOL CELL ENDOCRINOL., (20130711), vol. 377, no. 1-2, pages 93 - 102
DESCRIPTION- BOULIANNE ET AL., NATURE, (1984), vol. 312, pages 643 - 646
DESCRIPTION- BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
DESCRIPTION- CABILLY ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 3273 - 3277
DESCRIPTION- ENGVALL ET AL., IMMUNOCHEM., (1971), vol. 8, page 871
DESCRIPTION- GREEN, LL, J. IMMUNOL. METHODS, (1999), vol. 231, pages 11 - 25
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, page 495
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, pages 495 - 497
DESCRIPTION- KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001
DESCRIPTION- LACEY ET AL., NATURE REVIEWS, (2012), vol. 11, pages 401 - 419
DESCRIPTION- LEWIS ET AL., MOL. IMMUNOL., (1995), vol. 32, pages 1065 - 1072
DESCRIPTION- LIU ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 3439 - 3443
DESCRIPTION- MORRISON ET AL., PROC. NATL. ACAD. SCI., (1985), vol. 81, pages 6851 - 6855
DESCRIPTION- MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
DESCRIPTION- MULLER, METH. ENZYMOL., (1983), vol. 92, pages 589 - 601
DESCRIPTION- NEUBERGER ET AL., NATURE, (1985), vol. 314, pages 268 - 270
DESCRIPTION- PARDOLL; BECKERLEG, IMMUNITY, (1995), vol. 3, page 165
DESCRIPTION- RAZ ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, page 9519
DESCRIPTION- WAHL ET AL., J. NUCL. MED., (1983), vol. 24, pages 316 - 325
DESCRIPTION- WANG ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, page 4156
INTERNATIONAL-SEARCH-REPORT- Richard Pazdur, "FDA Approval for Denosumab", (20130702), National Cancer Institute, URL: http://www.cancer.gov/cancertopics/druginfo/fda-denosumab, (20141009), XP002730881 [A] 19,44 * the whole document *
INTERNATIONAL-SEARCH-REPORT- STAHL PETER J ET AL, "Contemporary management of male infertility.", ANNUAL REVIEW OF MEDICINE, (2012), vol. 63, ISSN 1545-326X, pages 525 - 540, XP002730908 [A] 1-44 * page 533 - page 537 *
INTERNATIONAL-SEARCH-REPORT- LEE SUN-KYEONG ET AL, "1,25 (OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1alpha and receptor activator of NF-kappaB ligand production in osteoblasts", JOURNAL OF IMMUNOLOGY, (20020901), vol. 169, no. 5, ISSN 0022-1767, pages 2374 - 2380, XP002730880 [A] 1-44 * figure 7 *
OPPOSITION- "13-19 Hodentumoren", E. Nieschlag et al, Andrologie Grundlagen und Klinik der reproduktiven Gesundheit des Mannes, (20090000), page 233, XP055737849
OPPOSITION- "13.19 Hodentumoren", E. Nieschlag et al, Andrologie Grundlagen und Klinik der reproduktiven Gesundheit des Mannes, (20090000), page 237, XP055737857
OPPOSITION- "6.3 atiologie", Dieter Jocham et al, PRAXIS DER UROLOGIE IN ZWEI BÄNDEN, (20070000), vol. II, page 465, XP055737855
OPPOSITION- "chapter 18", E. Nieschlag (Hrsg.) H. M. Behre (Hrsg.) S. Nieschlag (Hrsg.), Andrologie Grundlagen und Klinik der reproduktiven Gesundheit des Mannes, (20090000), pages 345 - 346, XP055737853
OPPOSITION- DUBOIS et al., "New Drug Mechanisms", Br. J. Clin. Pharmacol., (20110000), vol. 71, no. 6, pages 804 - 806, XP055737501
OPPOSITION- KARTSOGIANNIS et al., "Localization of RANKL (Receptor Activator of NFkB Ligand) mRNA and Protein in Skeletal and Extraskeletal Tissue", Bone, (19990000), vol. 25, no. 5, pages 525 - 534, XP055737480
OPPOSITION- ORWOLL et al., "A Randomized, Placebo-Controlled Study of theEffects of Denosumab for the Treatment of Men with Low Bone Mineral Density", J. Clin. Endocrinol Metab, (20120000), vol. 97, no. 9, pages 3161 - 3169, XP055737489
OPPOSITION- "Vaterschaft trotz Hodenkrebs", (20051102), URL: https://www.netdoktor.at/gesundheit/maenner/vaterschaft-trotz-hodenkrebs-6825151, XP055737851
OPPOSITION- KAUFMAN et al., "Treatment of osteoporosis in men", Bone, (20130000), vol. 53, no. 1, pages 134 - 144, XP055737863
OPPOSITION- SMITH et al., "Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer", J. Urol., (20090000), vol. 182, no. 6, pages 2670 - 2675, XP026747901
OPPOSITION- FIZAZI et al., "Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study", Lancet, (20110000), vol. 377, no. 9768, pages 813 - 822, XP055415066
OPPOSITION- "63 infertilitat des Mannes", Dieter Jocham et al, Praxis der Urologie In zwei Banden, (20070000), vol. II, pages 461 - 462, XP055737858
OPPOSITION- PEPENE et al., "Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism", Clin. Invest. Med., (20110000), vol. 34, no. 4, pages E232 - E237, XP055737861

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents